Treatment of advanced Parkinsons disease in the United States: A cost-utility model

Clinical Drug Investigation

Volumn 30, Issue 11, 2010, Pages 789-798

  Groenendaal, Huybert ^a   Tarrants, Marcy L ^b   Armand, Christophe ^c  

^a Vose Consulting   (United States)

^b Teva Neuroscience Inc   (United States)

^c Lundbeck   (France)

Author keywords

Carbidopa; Catechol O methyltransferase inhibitors; Cost utility; Dopamine receptor agonists; Elderly; Entacapone; Levodopa; Monoamine oxidase B inhibitors; Parkinsons disease; Rasagiline; therapeutic use; treatment

Indexed keywords

CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; ENTACAPONE; LEVODOPA; RASAGILINE; ANTIPARKINSON AGENT; CARBIDOPA; CATECHOL DERIVATIVE; INDAN DERIVATIVE; NITRILE;

ADJUVANT THERAPY; ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH STATUS; HUMAN; MONOTHERAPY; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; UNITED STATES; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DISEASE COURSE; DRUG ADMINISTRATION; DRUG COMBINATION; ECONOMICS; PATHOPHYSIOLOGY; QUALITY OF LIFE; STATISTICAL MODEL; STATISTICS; TIME; TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; CARBIDOPA; CATECHOLS; COST SAVINGS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG THERAPY, COMBINATION; HUMANS; INDANS; LEVODOPA; MARKOV CHAINS; MODELS, ECONOMIC; NITRILES; PARKINSON DISEASE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; STOCHASTIC PROCESSES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 77956454678     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11538520-000000000-00000     Document Type: Article

References (24)

1. Tanner CM, Goldman SM. Epidemiology of Parkinsons disease. Neurol Clin 1996; 14: 317-35
2. OertelWH,QuinnNP. Parkinsonism. In: Brandt T,Caplan LR, Dichgans J, et al., editors.Neurological disorders: course and treatment. San Diego (CA): Academic Press, 1996: 715-72
3. Hudry J, Rinne JO, Kerä nen T, et al. Cost-utility model of rasagiline in the treatment of advanced Parkinsons disease in Finland. Annals Pharmacother 2006; 40: 651-7
4. Dodel RC, Singer M, Kohne-Volland R, et al. The economic impact of Parkinsons disease: an estimation based on a 3-months prospective analysis. Pharmacoeconomics 1998; 14: 299-312
5. Vose D. Risk analysis, a quantitative guide. 3rd ed. Hoboken (NJ): John Wiley & Sons, 2008
6. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health andmedicine. NewYork: Oxford University Press, 1996
7. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinsons disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomized, double-blind, parallel-group trial. Lancet 2005; 365: 947-54
8. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the "DEALE"): I. Validation of the method. Am J Med 1982; 73: 833-8
9. Herlofson L, Lie SA, Arsland D, et al. Mortality and Parkinson disease: a community based study. Neurology 2004; 62: 937-42
10. Palmer CS, Schmier JK, Snyder E, et al. Patient preferences and utilities for off-time outcomes in the treatment of Parkinsons disease. Qual Life Res 2000; 9: 819-27
11. Orsini L, Castelli-Haley J, Kennedy S, et al. Healthcare utilization and expenditures among privately insured patients with Parkinsons disease in the US. Poster presented at the 8th Annual Meeting of the Movement Disorder Societys International Congress; Jun 2004; Italy
12. US Department of Labor: Bureau of Labor Statistics. Consumer price index - all urban consumers (current series). 2006 [online]. Available from URL: http://data.bls.gov/PDQ/outside.jsp?survey=cu [Accessed 2009 Apr 1]
13. Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilization in patients with Parkinsons disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 2001; 19: 1013-38
14. LePen C, Wait S, Moutard-Martin F, et al. Cost of illness and disease severity in a cohort of French patients with Parkinsons disease. Pharmacoeconomics 1999; 16:59-69
15. Whetten-GoldsteinK, Sloan F, Kulas E, et al. The burden of Parkinsons disease on society, family, and the individual. J Am Geriatr Soc 1997; 45: 844-9
16. Kerä nen T, Kaakkola S, Sotaniemi K, et al. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 2003; 9: 163-8
17. Huse DM, Schulman K, Orsini L, et al. Burden of illness in Parkinsons disease. Mov Disord 2005; 20: 1449-54
18. Scheife RT, Schumock GT, Burstein A, et al. Impact of Parkinsons disease and its pharmacologic treatment on quality of life and economic outcomes. Am J Health-Syst Pharm 2000; 57: 953-62
19. Red Book for Windows. Version 61127, vol. 50. Montvale (NJ): Thomson PDR, 2009 Jan
20. World Health Organization Collaborating Centre for Drug Statistics Methodology [online]. Available from URL: http://www.whocc.no/atcddd/ [Accessed 2009 Jul 31]
21. Hoerger TJ, Bala MV, Rowland C, et al. Cost effectiveness of pramipexole in Parkinsons disease in the US. Pharmacoeconomics 1998; 14: 541-57
22. Müller T, VoX B, Hellwig K, et al. Treatment benefit and daily drug costs in Parkinsons disease clinics. CNS Drugs 2004; 18 (2): 105-11
23. Siebert U, Bornschein B, Walbert T, et al. Systematic assessment of decision models in PD. Value Health 2004; 7: 610-26
24. Grosset KA, Reid JL, Grosset DG. Medicine-taking behavior: implications of suboptimal compliance in Parkinsons disease. Mov Disord 2005; 20 (11): 1397-404